BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20


BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics CCCC and lower its price target from $57.00 to $20.00.

Shares of C4 Therapeutics are trading down 20.49% over the last 24 hours, at $9.00 per share.

A move to $20.00 would account for a 122.22 increase% shift from the current share price.

About C4 Therapeutics

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.






Posted In: Analyst RatingsBZI-AAR-UPDATE